Moawia Mohammed Ali Elhassan, Associate Professor at University of Gezira, Consultant of Clinical and Radiation Oncology at Universal Hospital Sudan, shared a post on LinkedIn about a recent article by Martin J van den Bent et al, published in The Lancet Oncology:
“Practice-Changing Update in Neuro-Oncology: CATNON Trial Results
The long-awaited long-term follow-up from the CATNON trial has recently been published in The Lancet, providing definitive clarity on the management IDHmt astrocytomas.
This trial investigated the benefit of the addition of concurrent or adjuvant TMZ to RT in patients with anaplastic astrocytoma, focusing on the individuals with IDHmt tumours.
The study confirms that RT (59.4 Gy in 33 fxs) followed by 12 cycles adjuvant TMZ—without the use of concurrent TMZ during RT—significantly improves OS for patients with aggressive IDHmt astrocytoma.
No benefit of TMZ, neither concurrent nor adjuvant, was observed in participants with IDH wild-type tumours.”
Title: Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Authors: Martin J van den Bent, Santoesha A Ghisai, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Jean-François Baurain, Warren P Mason, Helen Wheeler, Emeline Tabouret, Sanjeev Gill, Matthew Griffin, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap C Reijneveld, Roelien H Enting, Sébastien Tran, Thierry Lesimple, Martin Kocher, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Youri Hoogstrate, Sarah Nuyensak, Vassilis Golfinopoulos, C Mircea S Tesileanu, Thierry Gorlia, Pim French, Brigitta G Baumert
Read the Full Article on The Lancet Oncology
More posts featuring Moawia Mohammed Ali Elhassan.